An observational study in Gastric Bypass Surgery, Revisional Bariatric Surgery and Complications After Bariatric Surgery, sponsored by Vrinnevi Hospital. Active, not recruiting at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-20.
Sponsored by Vrinnevi Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Objective:
To investigates incidence, indications, symptom relief, complications, and weight outcomes after Roux-en-Y gastric bypass (RYGB) reversal.
Background:
RYGB is an effective treatment for obesity, but in rare cases may be associated with severe long-term complications requiring RYGB reversal. Evidence on incidence and outcomes is limited.
Methods:
This nationwide, multi-center, retrospective cohort study included all patients undergoing RYGB reversal in Sweden between 2007 and 2023. Data were obtained from the Scandinavian Obesity Surgery Registry (SOReg) and medical records.
Vrinnevi Hospital is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
National registry-based cohort
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Included patients were adults (≥ 18years) who underwent reversal of RYGB between 2007 and 2023. Exclusion criteria included emergency reversal due to bowel ischemia, reversal following other bariatric procedures (e.g. gastric banding), or partial/functional reversals (e.g., gastro-gastric fistula or anastomosis between the Roux-limb and gastric remnant, without full reversal of RYGB)
Symptom relief
Symptom relief is classified as no, partial, or complete improvement. Complete improvement was defined as full resolution of the index symptom (e.g., cessation of hypoglycemia, pain-free status without analgesics). Partial improvement denoted a clinically meaningful reduction in symptom severity or frequency that did not meet criteria for complete resolution. No improvement indicated persistent symptoms.
Time frame: Through study completion, an average of 2 years.
Indications for surgery
Indications are categorized as abdominal pain, malnutrition, gastrointestinal symptoms, post-bariatric hypoglycemia, and psychological distress, and reported as number (frequencies).
Time frame: Through study completion, an average of 2 years.
Weight outcome after surgery
Weigth \[in kilograms\] will be reported at baseline (before surgery), at one year follow-up, and two-year follow-up.
Time frame: Through study completion, an average of 2 years.
Complications
Complications after surgery are registered as any complication and major complication (defined as Clavien-Dindo classification \>=3b), presented as number (frequencies).
Time frame: At 30-day follow-up and one-year follow-up after surgery.
Height
Height (in meters) will be used to report BMI (in kg/m2).
Time frame: Through study completion, an average of 2 years
BMI
Weight (in kilograms) and height (in meters) will be combined to report BMI (in kg/m2) at baseline (before surgery), at one year follow-up, andat two-year follow-up.
Time frame: Through study completion, an average of 2 years.
Surgical technique
* Surgical approach (laparoscopic or open procedure) * Handling of the Roux limb (resection or reconnection) * Jejuno-jejunostomy technique (stapled/handsewn) * Pyloroplasty/pyloromyotomy (yes/no) * Gastro-gastrostomy technique (stapled/handsewn) * Blood loss during surgery (ml) * Operation time (minutes) -all data presented as number (frequencies)
Time frame: Perioperative/periprocedural
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Since reversal of RYGB is a rare procedure the risk of identifying individual patients is considerable even if data are pseudonymized.
Started Nov 2025 (actual). Primary completion is estimated for Mar 2026, 4 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vrinnevi Hospital